Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company worked to absorb cost increases through price revisions and strengthened value-added proposals for existing products, expanded sales of new products, and increased domestic and overseas sales. In Pharmaceuticals, royalty income, lower research and development expenses, and higher profits at overseas subsidiaries contributed to results. On the other hand, higher raw material costs, drug price revisions, promotional expenses for newly launched products, impairment losses of ¥24,488 million, and losses on the reduction of the book value of fixed assets of ¥11,024 million affected profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥1,173,688 million (YoY +1.7%) |
| Operating profit | ¥93,307 million (YoY +10.2%) |
| Ordinary income | ¥96,571 million (YoY +17.7%) |
| Profit attributable to owners of the parent | ¥35,076 million (YoY -31.0%) |
| Net income per share | ¥129.42 |
| Operating Margin | 7.9％ |
| Equity ratio | End of the current fiscal period 61.2％ / End of previous period 63.2％ |
| Total assets | ¥1,261,759 million |
| Net assets | ¥817,552 million |
| Cash flows from operating activities | ¥56,522 million |
| Cash flows from investing activities | ¥-110,375 million |
| Cash flows from financing activities | ¥34,603 million |
| Cash and cash equivalents at end of period | ¥49,611 million |
| Full-year earnings forecast | Net Sales ¥1,212,000 million (YoY +3.3%) / Operating profit ¥100,000 million (YoY +7.2%) / Ordinary income ¥101,000 million (YoY +4.6%) / Net income ¥62,500 million (YoY +78.2%) |
| Annual Dividend Forecast | ¥100 per share → ¥110 per share（+10.0%） |
| Payout ratio | 81.1％ |
| Shareholder Return Policy | The company aims for total payout ratios of at least 50% in each fiscal year and continued increases in dividends per share. |
| Segment revenue | Food ¥941,470 million (YoY +1.9%) / Pharmaceuticals ¥232,218 million (YoY +1.1%) |
| Segment profit | Food ¥68,746 million (YoY +6.4%) / Pharmaceuticals ¥30,463 million (YoY +23.1%) |
| Depreciation and amortization | ¥54,954 million |
| Impairment loss | ¥24,488 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,990 million, Subsidy Income ¥11,023 million, Other ¥1,143 million / Extraordinary loss Loss on disposal of fixed assets ¥3,237 million, Loss on reduction of fixed assets ¥11,024 million, Impairment Losses ¥24,488 million, Other ¥3,937 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 2 / Company name Meiji Food Asia Pacific Pte. Ltd., Meiji Pharma Asia Pte. Ltd. / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 282,200,000 |
| Treasury Shares at Period-End | 11,098,044 |
| Factors Behind Changes in Business Performance | The company worked to absorb cost increases through price revisions and strengthened value-added proposals for existing products, expanded sales of new products, and increased domestic and overseas sales. In Pharmaceuticals, royalty income, lower research and development expenses, and higher profits at overseas subsidiaries contributed to results. On the other hand, higher raw material costs, drug price revisions, promotional expenses for newly launched products, impairment losses of ¥24,488 million, and losses on the reduction of the book value of fixed assets of ¥11,024 million affected profit. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and operating profit benefited from efforts to absorb cost increases through price revisions, value-added proposals for existing products, expanded sales of new products, and increased domestic and overseas sales. Net profit was affected by a substantial increase in extraordinary losses, mainly due to higher impairment losses and losses on the reduction of the book value of fixed assets.